Related Experiment Video
Updated: Jan 12, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Human Papilloma Virus Does Not Fully Inactivate p53 Cellular Activity in HNSCC
Jovanka Gencel-Augusto1,2, Hua Li1,2, Liam C Woerner1,2
1Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco (UCSF), San Francisco, California, USA.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is a major global health challenge. Inactivation of the tumor suppressor p53 is the most frequent driver event in this malignancy. p53 inactivation occurs either through TP53 mutations in human papilloma virus (HPV)-negative cases or via HPV-mediated p53 degradation in HPV-positive (HPV+) cases, where most tumors retain a wild-type (WT) TP53 allele. This underscores the critical role ofp53-regulated processes in HNSCC pathogenesis. Clinically, HPV+ HNSCC has significantly better outcomes than HPV-negative disease. However, approximately 10% of HPV+ HNSCC tumors harbor TP53 mutations, suggesting selective pressure to suppress p53 signaling beyond viral degradation. In this study, we demonstrate that HPV+ TP53-WTHNSCC cells have residual, tumor suppressive p53 activity. Clinically, patients with HPV+ TP53-WT tumors exhibit significantly better survival than those with HPV+ TP53-mutantor HPV-negative tumors. In vitro, WT p53 loss in HPV+ HNSCC cells enhances proliferation, migration, and invasion, and transcriptomic analysis confirms ongoing p53-dependent gene regulation. HPV+ TP53-WT tumors also display tumor-suppressive gene methylation patterns, fewer chromosomal alterations, and reduced PI3K-AKT signaling compared to TP53-mutant HPV+ cases. Notably, p53 loss increases expression of the PI3K catalytic subunit p110α, suppresses the PI3K-AKT inhibitor INPP5D, and sensitizes cells to pharmacologic PI3Kinhibition. Together, our findings challenge the prevailing view that p53 is completely inactivated in HPV+ HNSCC and reveal tumor suppressive, p53-driven mechanisms that persist in these tumors. These insights highlight a potential role for TP53-based stratification in guiding treatment decisions and suggest new therapeutic vulnerabilities in HPV+ HNSCC.
Insights
Head and neck squamous cell carcinoma (HNSCC) with wild-type TP53 and human papillomavirus (HPV+) shows residual p53 activity, improving patient survival. Loss of this p53 function in HPV+ HNSCC promotes tumor growth and suggests new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a significant global health concern.
- Tumor suppressor p53 inactivation is a frequent event in HNSCC, occurring via TP53 mutations or human papillomavirus (HPV)-mediated degradation.
- HPV-positive (HPV+) HNSCC generally has better outcomes than HPV-negative HNSCC, but a subset of HPV+ tumors harbor TP53 mutations.
Purpose of the Study:
- To investigate the role and extent of p53 activity in HPV+ HNSCC, particularly in tumors with wild-type (WT) TP53.
- To explore the functional consequences of p53 loss in HPV+ HNSCC.
- To identify potential therapeutic vulnerabilities associated with p53 status in HPV+ HNSCC.
Main Methods:
- Analysis of clinical outcomes based on HPV and TP53 mutation status.
- In vitro experiments assessing proliferation, migration, and invasion of HPV+ HNSCC cells with varying p53 status.
- Transcriptomic analysis to identify p53-dependent gene regulation.
- Assessment of genomic alterations and signaling pathway activity (e.g., PI3K-AKT).
Main Results:
- HPV+ TP53-WT HNSCC cells exhibit residual tumor suppressive p53 activity.
- Patients with HPV+ TP53-WT tumors show significantly better survival compared to those with HPV+ TP53-mutant or HPV-negative tumors.
- Loss of WT p53 in HPV+ HNSCC enhances tumor cell proliferation, migration, and invasion, alters methylation patterns, increases chromosomal instability, and impacts PI3K-AKT signaling.
Conclusions:
- p53 is not completely inactivated in all HPV+ HNSCC, with residual tumor suppressive functions present in WT cases.
- p53 loss in HPV+ HNSCC contributes to aggressive tumor behavior and altered signaling pathways, including PI3K-AKT.
- TP53 status may be a valuable biomarker for stratifying HPV+ HNSCC patients and identifying novel therapeutic targets, such as PI3K pathway inhibition.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Inhibition of Cdk Activity
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

